Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Recently, miraculous therapy approaches involving adeno-associated virus (AAV) for incurable diseases such as spinal muscular atrophy and inherited retinal dysfunction have been introduced. Nonreplicative, nonpathogenic, low rates of chromosome insertional properties and the existence of neutralizing antibodies are main safety reasons why the FDA approved its use in gene delivery. To date, AAV production always results in a mixture of nontherapeutic (empty) and therapeutic (DNA-loaded) full capsids (10-98%). Such existence of empty viral particles inevitably increases viral doses to human. Thus, the rapid monitoring of empty capsids and reducing the empty-to-full ratio are critical in AAV science. However, transmission electron microscopy (TEM) is the primary tool for distinguishing between empty and full capsids, which creates a research bottleneck because of instrument accessibility and technical difficulty. Herein, we demonstrate that atomic force microscopy (AFM) can be an alternative tool to TEM. The simple, noncontact-mode imaging of AAV particles allows the distinct height difference between full capsids (∼22 nm) and empty capsids (∼16 nm). The sphere-to-ellipsoidal morphological distortion observed for empty AAV particles clearly distinguishes them from full AAV particles. Our study indicates that AFM imaging can be an extremely useful, quality-control tool in AAV particle monitoring, which is beneficial for the future development of AAV-based gene therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.langmuir.3c00241DOI Listing

Publication Analysis

Top Keywords

empty capsids
12
full capsids
12
aav particles
12
dna-loaded full
8
adeno-associated virus
8
atomic force
8
force microscopy
8
empty
7
aav
7
capsids
6

Similar Publications

Preparative choline-based anion-exchange chromatography for enrichment of full adeno-associated virus capsids.

J Chromatogr A

October 2025

Tosoh Bioscience LLC, 3604 Horizon Drive, King of Prussia, PA 19406, USA. Electronic address:

Recombinant adeno-associated virus (AAV) vectors have emerged as powerful gene delivery tools for the treatment of genetic disorders. However, the production of high-quality AAV vectors still poses significant challenges. In upstream manufacturing, AAV genome packaging typically results in a diverse pool of empty and partially filled capsids, as well as the desired functional virions.

View Article and Find Full Text PDF

Accelerated Adeno Associated Virus Upstream Process Development From High-Throughput Systems to Clinical Scale.

Biotechnol Bioeng

August 2025

BioProcess Sciences, Pharma Services, Viral Vector Services, Thermo Fisher Scientific, Plainville, Massachusetts, USA.

Adeno-associated virus (AAV) is one of the most common delivery systems used in gene therapy. Challenges in the development and manufacturing of AAVs include high cost of goods (COGs) per dose, process scalability, speed to market, and process-related impurities such as empty capsids. This article presents a streamlined approach to developing and scaling AAV upstream production process via triple transfection from bench scale to commercial volumes exceeding 1,000 L.

View Article and Find Full Text PDF

Picornavirus cell entry requires a series of capsid protein conformational changes leading to genome uncoating. For enteroviruses, receptor binding triggers the transition from a full (F) capsid to an altered (A) particle before releasing its genome and finally converting it into an empty (E) particle. In contrast, non-enteroviruses, such as Aphthovirus, Cardiovirus, or Seneca Valley virus, release their genomes by dissociating the capsid into pentamers.

View Article and Find Full Text PDF

A proof of concept study on the use of online two-dimensional SEC-UV-RPLC-MS method for the multi-attribute characterization of gene therapy products.

Anal Chim Acta

October 2025

School of Pharmaceutical Sciences, University of Geneva, CMU, Rue Michel Servet 1, 1211, Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, CMU, Rue Michel Servet 1, 1211, Geneva, Switzerland. Electronic address:

Background: Recombinant adeno-associated virus (rAAV) vectors have emerged as a leading platform for gene therapy, supported by several FDA-approved products and numerous clinical trials. Due to their biological complexity and heterogeneity, rigorous analytical methods are essential to ensure the quality, safety, and efficacy of rAAV-based products. Critical quality attributes (CQAs) such as aggregation, full/empty capsid ratios, viral protein composition, and post-translational modifications (PTMs) must be monitored comprehensively.

View Article and Find Full Text PDF

Parvoviruses are single-stranded DNA viruses that have been modified to serve as vehicles for therapeutic transgene delivery in the form of recombinant Adeno-Associated Virus (rAAV2) vectors or rodent parvovirus-derived oncolytic agents. Infection with viruses of the Parvoviridae family induces a cellular DNA Damage Response (DDR) signal that supports virus replication. However, it remains unknown whether rAAV2 vectors or non-replicative wild-type AAV2 (wtAAV2) genomes induce cellular DDR signals, which might be deleterious to the cell.

View Article and Find Full Text PDF